In Bloomberg BNA Medical Research Law & Policy Report,Litigators Review Corruption Risks Facing Sponsors and Service Providers in the Clinical Trial Industry
Health care partner Mark Barnes (Boston) business & securities litigation partner Nicholas Berg, and government enforcement associate Brendan Hanifin (both of Chicago) co-authored an article published by Bloomberg BNA’s Medical Research Law & Policy Report on Jan. 6. The article, titled “Corruption Risks in International Clinical Trials: Navigating Between Anti-Bribery Laws and Local Circumstances,” examines corruption risks in international clinical trials and discusses several proactive steps that clinical trial sponsors and services providers may consider to mitigate the risk.